NASDAQ · SERA

Sera Prognostics, Inc.

$2.05 $0.00 (+0.00%) 1D Market open

Key Metrics

$80.28M
Market cap
P/E · TTM
$57.00K
Revenue · TTM
−$32.14M
Net income
EPS · TTM $-0.77
Dividend yield
Free cash flow −$27.58M
Beta · 1Y 1.15
EBITDA · TTM −$35.70M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 22
    The stock moved +15.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 22
  • May 13
    From its Feb 3 high, the share price fell 44%.

    Peak close $2.82 on Feb 3; trough close $1.59 on May 13. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -44%
  • Apr 6
    The stock moved +14.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 6

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$80.28M
Enterprise value
Shares outstanding39.2M
52-wk range$1.56 – $3.95
Avg volume · 20D238.9K
Net cash
Book value / share$1.61
IndustryServices-Medical Laboratories
ExchangeNASDAQ
About Sera Prognostics, Inc.
IPO dateJul 15, 2021
Employees72

Sera Prognostics Inc is a health diagnostic company.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S1,408.34
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -64,235.1%
Net -56,386.0%
FCF -48,377.2%
ROE / ROIC -55.7% · —

Financial Health

Current ratio2.12
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$26.31M

Cash Flow · TTM

Operating CF −$26.84M
Capex −$731.00K
Free cash flow −$27.58M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

-3.9
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings